Scarica l'app Stockscreener
12.17
0.75%
0.09
Precedente Chiudi:
$12.08
Aprire:
$12.2
Volume 24 ore:
145.35K
Relative Volume:
0.60
Capitalizzazione di mercato:
$353.17M
Reddito:
$66.98M
Utile/perdita netta:
$-71.54M
Rapporto P/E:
-3.798
EPS:
-3.2043
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
-4.17%
1M Prestazione:
-16.87%
6M Prestazione:
+57.03%
1 anno Prestazione:
+106.97%
Intervallo 1D:
$12.07
$12.68
Intervallo di 1 settimana:
$12.04
$13.19
Portata 52W:
$4.09
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Nome
Enanta Pharmaceuticals Inc
Settore
Industria
Telefono
617 607 0800
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
12.17 | 350.55M | 66.98M | -71.54M | -18.46M | -3.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Iniziato | JP Morgan | Overweight |
| 2025-10-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2023-08-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Iniziato | Evercore ISI | Underperform |
| 2020-08-28 | Ripresa | ROTH Capital | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-27 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Iniziato | Wolfe Research | Outperform |
| 2019-04-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-12-13 | Iniziato | Berenberg | Hold |
| 2018-06-06 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-11 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | Barclays | Underweight |
| 2015-10-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
Mostra tutto
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Aug Catalysts: Can Enanta Pharmaceuticals Inc be recession proofM&A Rumor & Entry Point Confirmation Alerts - baoquankhu1.vn
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Weekly Recap: How sensitive is Enanta Pharmaceuticals Inc to inflation2026 Movers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Trend Recap: Can Enanta Pharmaceuticals Inc sustain earnings growth2026 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
Free cash flow per share of Enanta Pharmaceuticals, Inc. – FWB:9EP - TradingView
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - MarketBeat
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
(ENTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Enanta Shareholders Approve Board Elections and Equity Plan - The Globe and Mail
Enanta (NASDAQ: ENTA) director receives 20,000-share stock option grant - Stock Titan
Enanta (ENTA) director Lesley Russell receives stock options on 20,000 shares - Stock Titan
Enanta (ENTA) director awarded stock option for 20,000 shares - Stock Titan
Enanta (ENTA) awards 20,000 stock options to director Yujiro S. Hata - Stock Titan
Enanta (ENTA) director receives grant of 20,000 options at $14.17 - Stock Titan
Enanta (NASDAQ: ENTA) awards director 20,000-share stock option grant - Stock Titan
Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978 - BioWorld MedTech
Aug Patterns: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Market WrapUp & Reliable Volume Spike Alerts - baoquankhu1.vn
Shareholders of Enanta (NASDAQ: ENTA) back equity plan expansion - Stock Titan
Enanta Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Pipeline Advances - Investing.com Canada
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Risk: Can Enanta Pharmaceuticals Inc reach all time highs this yearJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock resilient to inflationTrend Reversal & Free Expert Approved Momentum Trade Ideas - Naître et grandir
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Entry Recap: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
Risk Analysis: How sensitive is Enanta Pharmaceuticals Inc to inflationEarnings Miss & AI Optimized Trade Strategies - baoquankhu1.vn
Enanta Pharmaceuticals (ENTA) Gets a Buy from J.P. Morgan - The Globe and Mail
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference - BioSpace
Responsive Playbooks and the ENTA Inflection - Stock Traders Daily
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight - StreetInsider
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm - Barchart.com
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Levels Update: Should I trade or invest in Enanta Pharmaceuticals Inc2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Pelthos Therapeutics (PTHS) and Savara (SVRA) - The Globe and Mail
[EFFECT] ENANTA PHARMACEUTICALS INC SEC Filing - Stock Titan
ENTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Enanta Pharmaceuticals Inc. reach all time highs this yearNew Guidance & High Accuracy Swing Entry Alerts - mfd.ru
Understanding the Setup: (ENTA) and Scalable Risk - Stock Traders Daily
Is Enanta Pharmaceuticals Inc. (9EP) stock included in top ETFsJuly 2025 Outlook & AI Powered Market Trend Analysis - mfd.ru
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33 - Defense World
Aug Decliners: Is Enanta Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ENTA PE Ratio & Valuation, Is ENTA Overvalued - Intellectia AI
Enanta Pharmaceuticals (ENTA) CSO nets PSU and rTSRU share awards - Stock Titan
Can Enanta Pharmaceuticals Inc. (9EP) stock surprise with quarterly resultsTrade Analysis Summary & Long-Term Growth Portfolio Plans - mfd.ru
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equities Analysts Issue Forecasts for ENTA Q2 Earnings - MarketBeat
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Enanta (ENTA) Announces $150 Million Mixed Securities Shelf Registration - GuruFocus
Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):